Payment overview · 2025
General Payments
$1,515.63
89 reported records · 21 companies
Healthcare provider profile · identity verified
Keith Lyle Fuller, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · OPELIKA, AL · NPI 1730125527
Verified facts
What the public records show
CMS Open Payments records show Keith Lyle Fuller, D.O. received $1,515.63 in general payments during 2025 across 89 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 693 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Kerendia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1427 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Soliqua 100-33 by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $317.08 | 20.9% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $258.47 | 17.1% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $141.37 | 9.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.67 | 8.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.93 | 4.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.23 | 4.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.40 | 3.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.29 | 3.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.49 | 3.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.49 | 2.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $39.83 | 2.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.46 | 2.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $36.23 | 2.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.04 | 2.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.58 | 2.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.89 | 2.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.42 | 1.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.83 | 1.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.76 | 1.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.22 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.95 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,515.63 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $317.08 | 21 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $143.88 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $141.37 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $91.25 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.93 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.23 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.51 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.28 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $56.16 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $55.29 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.49 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.49 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.49 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.49 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $39.83 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $33.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.88 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.88 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 693 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 235 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 40 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 101 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 221 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 203 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 176 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 213 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
101 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
693 | 100 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
82 | 82 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
213 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
235 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
221 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
203 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
176 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1427 | 107 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
169 | 36 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3556 | 418 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2500 | 259 |
| Amlodipine Besylate | Amlodipine Besylate | 2183 | 228 |
| Pantoprazole Sodium | Pantoprazole Sodium | 2066 | 206 |
| Losartan Potassium | Losartan Potassium | 1770 | 222 |
| Trazodone Hcl | Trazodone Hcl | 1624 | 163 |
| Famotidine | Famotidine | 1614 | 114 |
| Potassium Chloride | Potassium Chloride | 1597 | 167 |
| Donepezil Hcl | Donepezil Hcl | 1539 | 99 |
| Eliquis | Apixaban | 1427 | 107 |
| Sertraline Hcl | Sertraline Hcl | 1396 | 99 |
| Furosemide | Furosemide | 1296 | 143 |
| Carvedilol | Carvedilol | 1194 | 129 |
| Lisinopril | Lisinopril | 1191 | 136 |
| Memantine Hcl | Memantine Hcl | 1149 | 76 |
| Omeprazole | Omeprazole | 1096 | 147 |
| Metoprolol Succinate | Metoprolol Succinate | 964 | 115 |
| Clopidogrel | Clopidogrel Bisulfate | 934 | 87 |
| Mirtazapine | Mirtazapine | 912 | 79 |
| Quetiapine Fumarate | Quetiapine Fumarate | 871 | 57 |
| Gabapentin | Gabapentin | 800 | 132 |
| Duloxetine Hcl | Duloxetine Hcl | 791 | 55 |
| Buspirone Hcl | Buspirone Hcl | 777 | 68 |
| Farxiga | Dapagliflozin Propanediol | 693 | 100 |
| Metformin Hcl | Metformin Hcl | 690 | 85 |
| Montelukast Sodium | Montelukast Sodium | 667 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 627 | 81 |
| Hydralazine Hcl | Hydralazine Hcl | 594 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 584 | 92 |
| Amiodarone Hcl | Amiodarone Hcl | 499 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 487 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 480 | 68 |
| Baclofen | Baclofen | 456 | 37 |
| Meloxicam | Meloxicam | 447 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 431 | 48 |
| Tramadol Hcl | Tramadol Hcl | 430 | 98 |
| Ropinirole Hcl | Ropinirole Hcl | 425 | 25 |
| Levetiracetam | Levetiracetam | 423 | 26 |
| Allopurinol | Allopurinol | 416 | 71 |
| Alprazolam | Alprazolam | 406 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 399 | 53 |
| Simvastatin | Simvastatin | 379 | 34 |
| Xarelto | Rivaroxaban | 360 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 353 | 83 |
| Prednisone | Prednisone | 347 | 61 |
| Fluoxetine Hcl | Fluoxetine Hcl | 342 | 54 |
| Ezetimibe | Ezetimibe | 341 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 327 | 42 |
| Metoclopramide Hcl | Metoclopramide Hcl | 311 | 13 |
| Sotalol | Sotalol Hcl | 296 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 283 | 39 |
| Divalproex Sodium | Divalproex Sodium | 277 | 16 |
| Bupropion Xl | Bupropion Hcl | 271 | 37 |
| Clonidine Hcl | Clonidine Hcl | 267 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 260 | 73 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 254 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 245 | 45 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 244 | 47 |
| Jardiance | Empagliflozin | 235 | 41 |
| Risperidone | Risperidone | 231 | 16 |
| Mounjaro | Tirzepatide | 221 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 217 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 62 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 213 | 41 |
| Ozempic | Semaglutide | 203 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 202 | 32 |
| Januvia | Sitagliptin Phosphate | 196 | 26 |
| Atenolol | Atenolol | 195 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 194 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 190 | 62 |
| Pentoxifylline | Pentoxifylline | 187 | 26 |
| Clonazepam | Clonazepam | 184 | 32 |
| Entresto | Sacubitril/Valsartan | 179 | 19 |
| Rexulti | Brexpiprazole | 176 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 170 | 20 |
| Alendronate Sodium | Alendronate Sodium | 169 | 19 |
| Celecoxib | Celecoxib | 169 | 38 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 169 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 162 | 13 |
| Lorazepam | Lorazepam | 162 | 49 |
| Latanoprost | Latanoprost | 158 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 156 | 30 |
| Ranolazine Er | Ranolazine | 156 | 11 |
| Torsemide | Torsemide | 155 | 22 |
| Bumetanide | Bumetanide | 154 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 26 |
| Aripiprazole | Aripiprazole | 149 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 149 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 144 | 42 |
| Olanzapine | Olanzapine | 144 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 139 | 23 |
| Benazepril Hcl | Benazepril Hcl | 136 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 133 | 60 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 127 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 126 | 44 |
| Spironolactone | Spironolactone | 120 | 25 |
| Nuplazid | Pimavanserin Tartrate | 114 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 111 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 111 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 32 |
| Propranolol Hcl | Propranolol Hcl | 110 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 20 |
| Valsartan | Valsartan | 109 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 103 | 21 |
| Amantadine | Amantadine Hcl | 102 | 13 |
| Linzess | Linaclotide | 101 | 31 |
| Zonisamide | Zonisamide | 101 | suppressed |
| Digoxin | Digoxin | 100 | suppressed |
| Myrbetriq | Mirabegron | 99 | suppressed |
| Nifedipine Er | Nifedipine | 99 | 27 |
| Ondansetron Odt | Ondansetron | 99 | 51 |
| Primidone | Primidone | 98 | suppressed |
| Lovastatin | Lovastatin | 97 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 96 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 96 | 12 |
| Verapamil Er | Verapamil Hcl | 93 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 91 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 88 | 17 |
| Lamotrigine | Lamotrigine | 88 | suppressed |
| Vascepa | Icosapent Ethyl | 86 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 85 | 48 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 85 | 12 |
| Sucralfate | Sucralfate | 84 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 82 | 82 |
| Bupropion Hcl | Bupropion Hcl | 81 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 80 | 16 |
| Carbamazepine | Carbamazepine | 77 | suppressed |
| Estradiol | Estradiol | 77 | 24 |
| Nortriptyline Hcl | Nortriptyline Hcl | 76 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 75 | 18 |
| Xifaxan | Rifaximin | 75 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 74 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 56 |
| Pregabalin | Pregabalin | 73 | 15 |
| Labetalol Hcl | Labetalol Hcl | 72 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 71 | suppressed |
| Fluconazole | Fluconazole | 71 | 44 |
| Gemtesa | Vibegron | 71 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 70 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 70 | 47 |
| Oxcarbazepine | Oxcarbazepine | 70 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 68 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 18 |
| Topiramate | Topiramate | 67 | 11 |
| Fentanyl | Fentanyl | 66 | suppressed |
| Methocarbamol | Methocarbamol | 66 | 26 |
| Cephalexin | Cephalexin | 65 | 55 |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Metolazone | Metolazone | 63 | suppressed |
| Ibuprofen | Ibuprofen | 62 | 20 |
| Dexlansoprazole Dr | Dexlansoprazole | 61 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 14 |
| Meclizine Hcl | Meclizine Hcl | 60 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 35 |
| Valacyclovir | Valacyclovir Hcl | 60 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 51 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | suppressed |
| Finasteride | Finasteride | 59 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 19 |
| Colestipol Hcl | Colestipol Hcl | 58 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 58 | 23 |
| Potassium Citrate Er | Potassium Citrate | 57 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 56 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 55 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 55 | 13 |
| Felodipine Er | Felodipine | 55 | suppressed |
| Levofloxacin | Levofloxacin | 55 | 51 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 55 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 54 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 53 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 53 | suppressed |
| Austedo | Deutetrabenazine | 52 | suppressed |
| Disopyramide Phosphate | Disopyramide Phosphate | 52 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 52 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 51 | suppressed |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Lumigan | Bimatoprost | 46 | suppressed |
| Glipizide | Glipizide | 45 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 45 | suppressed |
| Diazepam | Diazepam | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 43 | 11 |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Mupirocin | Mupirocin | 41 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 11 |
| Kerendia | Finerenone | 40 | 11 |
| Lidocaine | Lidocaine | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Cefdinir | Cefdinir | 38 | 32 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | suppressed |
| Insulin Lispro | Insulin Lispro | 38 | 11 |
| Colchicine | Colchicine | 37 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 37 | suppressed |
| Paliperidone Er | Paliperidone | 37 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 36 |
| Premarin | Estrogens, Conjugated | 35 | suppressed |
| Lacosamide | Lacosamide | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 31 |
| Phenobarbital | Phenobarbital | 34 | suppressed |
| Timolol Maleate | Timolol Maleate | 34 | suppressed |
| Enulose | Lactulose | 32 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 32 | 29 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Tresiba | Insulin Degludec | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 11 |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Letrozole | Letrozole | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 28 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Novolog | Insulin Aspart | 25 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Methazolamide | Methazolamide | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 13 |
| Brilinta | Ticagrelor | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 22 | suppressed |
| Levemir | Insulin Detemir | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 17 |
| Cefadroxil | Cefadroxil | 21 | 18 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Dayvigo | Lemborexant | 21 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Nucynta | Tapentadol Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Azathioprine | Azathioprine | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 15 |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Matzim La | Diltiazem Hcl | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 18 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Cholestyramine Light | Cholestyramine | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | 13 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 16 | 12 |
| Bicalutamide | Bicalutamide | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Edarbi | Azilsartan Medoxomil | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Nystop | Nystatin | 15 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 13 | suppressed |
| Nora-Be | Norethindrone | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Budesonide | Budesonide | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rinvoq | Upadacitinib | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,515.63 · 89 records | Otsuka America Pharmaceutical, Inc. | ACCRUFER, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, FANAPT, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, ZAVZPRET, ZORYVE | 28 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error